// App-Quantinova.ai

POS1049 (2022) : ASSESSING TREATMENT PATTERNS WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND PREDNISONE FOR PSORIATIC ARTHRITIS BY RACE/ETHNICITY

Researchers

Presenter

  • F. Ahmed

Principal Investigators

  • A. Ogdie

  • R. Fitzsimmons

  • D. Shin

  • J. Takeshita

Medical Centers

  • University of Pennsylvania, Department of Pharmacology, Philadelphia, United States

  • University of Pennsylvania, Department of Pharmacology, Philadelphia, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Alpha-methylacyl-CoA racemase

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Oraprine

  • Certolizumab pegol

  • Cyclosporine eent

  • Methotrexate

  • Risankizumab

  • leflunomide

  • Tasocitinib

  • secukinumab

  • Ustekinumab

  • Adalimumab

  • Apremilast

  • Infliximab

  • brodalumab

  • Etanercept

  • CHS-0214

  • guselkumab (IV)

  • Prednisone

  • Abatacept

  • golimumab

Outcome

  • N/A

Study Design

  • Multinational

  • Cross-Sectional

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved